Press release
Chronic Inflammatory Demyelinating Polyneuropathy Market Trends Highlight Clinical Trials, FDA Activity, and Global Market Expansion
Chronic Inflammatory Demyelinating Polyneuropathy
The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market is led by major players such as Grifols, CSL Behring, Octapharma, Baxter, and Kedrion S.p.A., who dominate the immunoglobulin therapy segment. Companies like Bio Products Laboratory Ltd, Shire, and Momenta Pharmaceuticals are expanding their neurology pipelines through innovation and partnerships. Mitsubishi Tanabe Pharma, Teijin Pharma, and Pfizer Inc. are advancing biologic and immunomodulatory treatments.
Download your exclusive sample report today: https://www.datamintelligence.com/download-sample/chronic-inflammatory-demyelinating-polyneuropathy-market?jd
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market M&A & Strategic Collaborations
1. argenx & Zai Lab partnership advancing Vyvgart Hytrulo launch in China
In May 2025, argenx SE and Zai Lab extended their collaboration to support the introduction of Vyvgart Hytrulo, the first subcutaneous FcRn blocker approved for CIDP, into Chinese clinics, aiming to improve treatment convenience and patient access in Greater China.
2. Takeda's GAMMAGARD LIQUID FDA label expansion
In January 2024, Takeda secured FDA approval for GAMMAGARD LIQUID as an IVIG therapy for adult CIDP, with expanded use gaining traction in early 2025 across North America and Europe under national immunoglobulin supply networks.
3. Argenx's Vyvgart Hytrulo boosts clinic readiness
In June 2025, ar¬genx's subcutaneous treatment received momentum in North America following strong real-world outcomes in the ADHERE trial, facilitating new partnerships with infusion centers and health providers for broader rollout.
As per our analysis, these developments underscore the CIDP market's emphasis on therapeutic innovation, label expansions, and cross-border market strategies.
Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/chronic-inflammatory-demyelinating-polyneuropathy-market?jd
Key Growth Drivers & Emerging Opportunities in the CIDP Market
• The rising global prevalence of autoimmune neuropathies is increasing demand for long-term CIDP management solutions.
• Advancements in immunoglobulin and FcRn-targeted therapies (e.g., Vyvgart Hytrulo) are reshaping treatment approaches.
• Improved diagnostic capabilities and earlier disease detection are expanding the eligible patient population.
• Ongoing clinical trials in monoclonal antibodies, subcutaneous therapies, and corticosteroid alternatives are opening new market opportunities.
• Strategic partnerships in emerging markets are enhancing access to CIDP therapies through localized production and distribution.
Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=chronic-inflammatory-demyelinating-polyneuropathy-market?jd
Regional Market Drivers for the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
North America leads the market due to strong reimbursement systems, high awareness of rare neurological disorders, and early adoption of IVIG and emerging biologics.
Europe benefits from government-funded treatment programs, centralized immunoglobulin supply chains, and robust rare disease surveillance systems.
Asia-Pacific is experiencing rapid growth with increased healthcare access, improving neurology diagnostics, and rising investments in autoimmune disorder research.
Latin America is driven by improving healthcare infrastructure and growing availability of immunoglobulin therapies through international health partnerships.
Middle East & Africa show steady progress due to expanding specialist care facilities and global aid programs supporting rare disease treatment access.
Unlock 360° Market Intelligence with DataM Subscription Services:
https://www.datamintelligence.com/reports-subscription
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis For Drug Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape
Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights, and developments to provide swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains, creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chronic Inflammatory Demyelinating Polyneuropathy Market Trends Highlight Clinical Trials, FDA Activity, and Global Market Expansion here
News-ID: 4104799 • Views: …
More Releases from DataM Intelligence 4Market Research LLP
Smart Classroom Market Set to Grow at 17.4% CAGR Driven by Digital Learning | To …
Global Smart Classroom Market is expected to reach at a CAGR of 17.4% within the forecast period (2024-2031).
According to DataM Intelligence has published a new research report on "Smart Classroom Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of…
Revenue Cycle Management Market to Reach US$ 291.19 Billion by 2033 at 12.4% CAG …
The global revenue cycle management market size reached US$ 102.16 billion in 2024 is expected to reach US$ 291.19 billion by 2033, growing at a CAGR of 12.4% during the forecast period 2025-2033.
According to DataM Intelligence has published a new research report on "Revenue Cycle Management Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top…
IT Asset Management Software Market to Reach US$ 4.14 Billion by 2033 at 7.11% C …
The global IT asset management software market reached US$ 2,132.33 million in 2023, with a rise to US$ 2,255.49 million in 2024, and is expected to reach US$ 4,139.20 million by 2033, growing at a CAGR of 7.11% during the forecast period 2025-2033.
According to DataM Intelligence has published a new research report on "IT Asset Management Software Market Size 2025". The report explores comprehensive and insightful Information about various…
Debt Collection Software Market Trends: Predictive Analytics, Cloud, and Omnicha …
Debt Collection Software Market is growing at a CAGR of 9.9 % in the forecast period (2024-2031)
According to DataM Intelligence has published a new research report on "Debt Collection Software Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of…
More Releases for CIDP
CIDP Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landsca …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Chronic Inflammatory Demyelinating Polyneuropathy pipeline constitutes 2+ key companies continuously working towards developing 4+ Chronic Inflammatory Demyelinating Polyneuropathy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across…
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Growth, Trends, …
Introduction
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare autoimmune disorder characterized by progressive weakness and impaired sensory function in the arms and legs due to damage to the myelin sheath surrounding peripheral nerves. Though uncommon, CIDP significantly affects patient quality of life and requires long-term management, often involving immunotherapy, corticosteroids, and plasma exchange.
Over the past decade, improved diagnostic capabilities, greater awareness of rare neurological diseases, and advancements in immunoglobulin therapies…
CIDP Market Emerging Trends and Growth Prospects 2034
Introduction
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) is a rare, immune-mediated neuropathy characterized by progressive or relapsing weakness, sensory loss, and impaired reflexes due to demyelination of peripheral nerves. Unlike acute Guillain-Barré syndrome, CIDP evolves over at least eight weeks and, without timely treatment, can lead to significant long-term disability. The condition encompasses typical CIDP and several clinical variants (e.g., MADSAM/Lewis-Sumner, DADS, pure motor, pure sensory), each with nuanced diagnostic and therapeutic…
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Market Insights and Co …
The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market sector is undergoing significant transformation, with substantial growth and technological advancements expected by 2031. According to a new in-depth market research report, the sector is poised for expansion, driven by various factors such as market size, share, and emerging trends.
This comprehensive report provides key insights into the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market, exploring critical market segmentation and definitions. It highlights the essential…
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment Market 2024-2 …
Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market is an uncommon autoimmune disorder affecting the peripheral nervous system. It manifests through the progressive weakening of muscles and the loss of sensation in extremities. The CIDP treatment market has shown consistent growth and is poised for significant expansion in the forthcoming years. In this comprehensive blog post, we will delve into the current scenario, regulatory framework, market dynamics, supplier landscape, drug distribution model,…
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Market Insights …
The market for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) was valued USD 968 Million in 2017 which is anticipated to reach USD 2,020.6 Million by 2030.
The total number of CIDP patients in the 7MM is projected to reach 55,113 by 2030 from 46,027 in 2019. The U.S. has the highest incidences of CIDP in the 7MM. In 2019, as per the data studied by Report Ocean, there were approximately 29,000…
